Yeung K K, Nederhoed J H, Tran B L, Di Gregorio S, Pratesi G, Bastianon M, Melani C, Riambau V, Bloemert-Tuin T, Hazenberg C E V B, van Herwaarden J A, Balm R, Lely R J, van der Meijs B B, Blankensteijn J D, Hoksbergen A W J, Jongkind V
Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
J Endovasc Ther. 2024 Jan 30:15266028241227392. doi: 10.1177/15266028241227392.
The aim of this study is to share preliminary experiences and outcomes with a novel custom-made fenestrated TREO Abdominal Stent-Graft System to treat juxtarenal and pararenal abdominal aortic aneurysms (AAAs).
Juxtarenal and pararenal AAA patients treated with the custom-made fenestrated TREO Abdominal Stent-Graft System were included from 4 high-volume European academic medical centers from June 2021 to September 2023. Technical success and 30-day/in-hospital mortality and complications were analyzed. Technical success was defined as successful endovascular implantation of the stent graft with preservation of antegrade flow to the target vessels, and absence of type 1 or 2 endoleak (EL) at the first postoperative computed tomography angiography (CTA).
Forty-two consecutive patients were included. The majority of the devices were constructed with 2 (N=4; 9.5%), 3 (N=9; 21.4%), or 4 (N=27; 64%) fenestrations. In 1 case, the device was constructed with a single fenestration (2.4%) and 1 device contained 5 fenestrations (2.4%); 17% had previous AAA repair. Target vessel cannulation with placement of a bridging stent was successful in all but 1 vessel (99, 3%). One aneurysm-related death occurred in the direct postoperative period and 2 limb occlusions necessitated reintervention during admission. In the median follow-up period of 101 (2-620) days, 3 more patients died due to non-aneurysm-related causes. Technical success was achieved in 90% of the cases. Nineteen ELs were seen on the first postoperative CT scan: 1 type 1b EL (N=1; 2%), 15 type 2 ELs (N=15; 36%), and 3 type 3 ELs (N=3%). Eleven patients received more than 1 CT scan during a median follow-up of 361 days (82-620): 3 type 2 ELs resolved and 1 type 3 EL was treated in this period. In the follow-up, 1 patient had a coagulation disorder that caused occlusions of the branches.
The results of the first experiences using the custom-made fenestrated TREO® Abdominal Stent-Graft System in Europe are promising. There was a low short-term mortality and morbidity rate in these patients of which 17% had previous AAA repair. Mid-term and long-term follow-up data are needed to evaluate endograft durability and performance.
This study shows the first experiences and short-term results of a novel low-profile custom-made device: the custom-made fenestrated TREO Abdominal Stent-Graft System. Showing these results and experiences can help the physicians in clinical decision-making for their patients.
